<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05039411</url>
  </required_header>
  <id_info>
    <org_study_id>CCSB-CT-PF-01-2021 (Ver_01)</org_study_id>
    <nct_id>NCT05039411</nct_id>
  </id_info>
  <brief_title>Safety of Allogeneic Human Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) to Treat Perianal Fistulas Patients With Crohn's Disease</brief_title>
  <official_title>A Phase I Study of the Safety of Allogeneic Human Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) for Perianal Fistulas in Patients With Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CryoCord Sdn Bhd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Malaya</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CryoCord Sdn Bhd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to demonstrate the safety of allogeneic human&#xD;
      umbilical cord mesenchymal stem cells (UC-MSCs) (product code: PF2020-CELL) administered by&#xD;
      intralesional injection in patients with Crohn's fistula. The secondary objective is to&#xD;
      compare the safety of a single/multiple UC-MSCs injection in a dose escalating manner as well&#xD;
      as on the efficacy of stem cells treatment (reepithelialization of the external openings of&#xD;
      fistula)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design and Investigation:&#xD;
&#xD;
      Dosage and mode of administration&#xD;
&#xD;
        1. First Dosage&#xD;
&#xD;
             -  125 million cells UC-MSCs to be injected&#xD;
&#xD;
             -  Procedure: Patients will undergo surgical localization, curettage of the fistulous&#xD;
                tract and closure of the internal opening, with intralesional injection of an&#xD;
                indicated dose of UC-MSCs&#xD;
&#xD;
        2. Second dosage&#xD;
&#xD;
             -  150 million cells UC-MSCs to be injected&#xD;
&#xD;
             -  Procedure: Patients will undergo surgical localization, curettage of the fistulous&#xD;
                tract and closure of the internal opening, with intralesional injection of an&#xD;
                indicated dose of UC-MSCs&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>First dose is125 million cells and only proceed to second dose of 150 million cells for patients clinically not recovered after 24 weeks from first dose.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of any treatment-emergent adverse events (TE-AEs)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Any composite of perianal sepsis, persistence of the fistula and allergic reaction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical healing</measure>
    <time_frame>24 and/or 48 weeks</time_frame>
    <description>Mainly on re-epithelialization of external opening</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">7</enrollment>
  <condition>Perianal Fistula Due to Crohn's Disease</condition>
  <condition>Fistula in Ano</condition>
  <arm_group>
    <arm_group_label>Human umbilical cord mesenchymal stem cells (UC-MSCs)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients to receive allogeneic UC-MSCs via intralesional injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Human umbilical cord mesenchymal stem cells (UC-MSCs)</intervention_name>
    <description>All patients to receive 1st dose of 125 million UC-MSCs and the 2nd dose of 150 million UC-MSCs only if patients have no clinical improvement post 24 weeks after 1st dose</description>
    <arm_group_label>Human umbilical cord mesenchymal stem cells (UC-MSCs)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult men and women age 18 years and above.&#xD;
&#xD;
          -  Diagnosis of perianal fistulae associated with Crohn's disease refractory to medical&#xD;
             therapy.&#xD;
&#xD;
          -  Presence of perianal fistula(s) with a maximum of 2 internal openings and a maximum of&#xD;
             3 external openings based on clinical assessment.&#xD;
&#xD;
          -  Fit for surgery.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Informed consent refusal.&#xD;
&#xD;
          -  Pregnancy or breastfeeding women.&#xD;
&#xD;
          -  Current diagnosis of active cancer or remission for less than 5 years.&#xD;
&#xD;
          -  Evidence of active sepsis or significant localised infection.&#xD;
&#xD;
          -  Patients with HIV, HBV, HCV or treponema infection, whether active or latent.&#xD;
&#xD;
          -  Patients with documented allergies.&#xD;
&#xD;
          -  Patients who have received infliximab or any other biologics in the 4 weeks before the&#xD;
             cell treatment administration.&#xD;
&#xD;
          -  Patients currently receiving, or having received within 1 month prior to enrollment&#xD;
             into this clinical trial, any investigational drug.&#xD;
&#xD;
          -  Patients with any other co-morbidity/ co-pathologies which is deemed as&#xD;
             contraindication to stem cells infusion (infection, administration of steroids).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>April Camilla Roslani, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Medicine, University of Malaya</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>April Camilla Roslani, Prof. Dr.</last_name>
    <phone>+603-7949 2050</phone>
    <email>april@ummc.edu.my</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Malaya Medical Centre</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <contact>
      <last_name>April Camilla Roslani, Prof. Dr.</last_name>
      <phone>+603-7949 2050</phone>
      <email>april@ummc.edu.my</email>
    </contact>
    <investigator>
      <last_name>April Camilla Roslani, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 1, 2021</study_first_submitted>
  <study_first_submitted_qc>September 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2021</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Perianal fistula</keyword>
  <keyword>Crohn's Disease</keyword>
  <keyword>Umbilical cord mesenchymal stem cells (UC-MSCs)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Rectal Fistula</mesh_term>
    <mesh_term>Fistula</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

